Dr Reddy's completes acquisition of Teva's US portfolio of 8 products

Pharma major expects some products to add to its topline in 2018; products were being divested by Teva as a condition to close acquisition with Allergan

Dr Reddy's announced that it has successfully completed the acquisition of eight Abbreviated New Drug Applications (ANDAs) in the US from Teva Pharmaceuticals Industries and an affiliate of Allergan Plc.

The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of acquisition of Allergan's generics business. In June, the company had entered an agreement with Teva to buy this portfolio of ANDAs for $ 350 million.

Dr Reddy's recently said some of these products would start adding to its top line some time in 2018. The portfolio is a mix of six ANDAs pending approval, one approved ANDA and one ANDA with tentative approval, and comprises complex generic products across diverse dosage forms. The combined sales of branded versions of products in the US were approximately $ 3.5 billion for the recent twelve months ending June 2016, according to IMS Health.

The products include Buprenorphine HCL/Naloxone HCL Sublingual Film(generic equivalent to Suboxone), Ethinyl estradiol/Ethonogestrel Vaginal Ring(generic equivalent of NuvaRing), Exetimibe/Simvastatin tablets (generic equivalent to Kombiglyze XR), Tobramycin Inhalation Solution(generic equivalent to Tobi), Phentermine HCL/Topiramate ER Capsules(generic equivalent to Qsymia), Imiquimod Topical Cream(generic equivalent to Zyclara 3.75 % Cream), and Ramelteon Tablets(generic equivalent to Rozerem).